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ABSTRACT
Objectives: Human papillomavirus infection is one of the most common sexually transmitted 
diseases. Long-term exposure to the HPV leads to development of high-grade squamous 
intraepithelial lesions that can eventually transform into cervical cancer. 
The aim of the study was to assess the HPV genotype distribution in patients with abnormal 
pap smear and provide prospective study. 
Material and methods: We obtained material from 674 women who registered to Specialist 
Medical Practice in the years 2008–2020. The sample for the molecular test was collected 
using combi brush and forwarded to the independent, standardized laboratory. HPV detection 
was done using PCR followed by DNA enzyme immunoassay and reverse hybridization line 
probe assay for virus genotyping. Sequence analysis was performed to characterize virus 
genotypes in HPV — positive samples. 
Results: We found that 53% of patients tested positive for HPV. The percentage decreased 
with age. The following HPV types were the most common: HPV — 16 (24.5%), HPV — 53 
(13.1%), HPV — 31 (10.3%), HPV — 51 (9.7%), HPV — 56 (9.5%). To our knowledge, this 
study is the largest assessment of HPV genotypes in Poland. 
Conclusions: Our results suggest that type-specific, high–risk HPV DNA — based screening 
should focus on HPV types 16, 31, 51, 56.
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Introduction
Cervical cancer remains the fourth most frequent cancer in women worldwide causing 
about 275,000 deaths annually [1, 2]. There are many factors affecting the development of 
this life-threatening disease, such as the socio-economic status, the age of first sexual 
intercourse, alcohol consumption or smoking, as well as genetic load, immunosuppression 
and a large number of pregnancies and births (especially for young women) [3]. However, the 
most important factor that has a significant impact on the development of cervical cancer is 
primarily persistent infection with high-risk HPV (HR HPV). It can lead to an uncontrolled 
course of infection and is the direct cause of the vast majority of cervical intraepithelial 
neoplasia and invasive cervical cancers. The oncogenic potential of particular HPV genotypes
has been acknowledged since the discovery of the definitive association of HPV as the 
indubitable etiological agent for development of SIL and cervical cancer. The role of human 
papillomavirus (HPV) in cervical cancer was established over 40 years ago [4, 5]. Genotypes 
16 and 18 are assumed to be responsible for about 70% of cervical cancer cases [6, 7]. 
A growing number of countries are replacing cervical cytology with molecular HPV 
testing as the primary screening modality. Both the American Cancer Society (ACS) and the 
European Society for Medical Oncology (ESCO) recommend a new pattern of cervical cancer
screening [8, 9]. According to ACS, HPV testing every five years in patients from 25 to 65 
years old is the preferred method. Pap-smear has been the standard method for cervical cancer
screening for over half of the century. It has reduced the incidence by 60–90% and the death 
rate by 90%. However, the limitation of Pap-smear is sensitivity (~50%) and a significant 
proportion of inadequate specimens. A pooled analysis of four randomized controlled trials of 
HPV-based cervical screening versus cytology showed 60–70% greater protection against 
invasive cancer in favor of HPV-test [10]. Thirteen HPV genotypes are recognized to be 
oncogenes with high-risk potential by the International Agency for Research on Cancer [11]. 
On a global scale, HPV infections cause more than half of infection-linked cancers 
among women and barely 5% in males. Vaccines against the high-risk HPV types 16 and 18 
represent the first prophylactic vaccines developed directly to prevent a major human cancer 
(cervical carcinoma). A significant decrease in the incidence of cervical cancer has been 
observed over the past several decades due to preventive measures and screening. 
Objectives
This paper summarizes the results of HPV DNA genotyping in the Wielkopolska region. 
So far, we do not have reliable data on the contribution of selected oncogenic HPV types in 
the formation of cervical pathology in the Polish population. As far as we are concerned, it is 
the largest analysis that has been described in Poland to date. Our aim is to provide 
distribution of particular HPV genotypes in specific age groups. This knowledge might enable
estimating the potential effectiveness of HPV vaccines as primary prevention.
MATERIAL AND METHODS
This retrospective study included 674 patients who registered to Specialist Medical 
Practice in the years 2008–2020 for regular cervical screening. Parallel to the Pap-smear, the 
women were tested for the presence of HPV which genotypes were later determined. The 
sample for a molecular test (Linear Array HPV Genotyping-Roche Diagnostics) was collected
from the external os of the cervix and vaginal wall with a use of combi brush. The obtained 
specimen was placed into a liquid-based medium Solution. An HPV test is a quality test that 
serves to identify high- risk HPV DNA of the following genotypes: 6, 11, 16, 18, 26, 31, 33, 
35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 68a, 68b, 69, 
70, 71, 72, 73, 81, 82, 83, 84, 87, CP6108, 90 in vitro. A positive result in molecular tests 
confirms the presence of DNA of at least one of the mentioned above oncogenic types of 
human papillomavirus in the collected specimens.
If needed, a following colposcopy and biopsy were performed. Specialist in gynecologic 
oncology with 10-year experience examined colposcopy with SmartOPTIC colposcope. Trial 
with a 5% aqueous solution of acetic acid as well as Schiller’s test with Lugol’s iodine were 
performed in all cases. The colposcopic images were evaluated according to Reid’s 
Colposcopic Index which assesses the color, lesion boundaries and surface, blood vessels, and
iodine test. All colposcopic images were archived. We used classification created by The 
International Federation of Cervical Pathology and Colposcopy and recommended by the 
Polish Society of Colposcopy and Cervical Pathophysiology.
Calculations were performed using the statistical package Statistica (ver. 13.3). Graphs 
were created with the help of Excel. Statistical hypotheses were verified at the level of 
significance of 0.05. The Shapiro-Wilk test was used to assess whether the data distribution is 
normal and Spearman's rho coefficient was used in order to analyze its correlation.  The 
correlation between individual genotypes and age groups was analyzed with a Chi-square test.
RESULTS
The mean age of the entire population was 34. A total of 359 patients (53.3%) tested 
positive for HPV DNA. The quantitative and percentage distribution of individual genotypes 
is presented in Table 1. Figure 1 shows the percentage distribution of HPV-positive women in 
each age group. The HPV genotype 16 and 53 were the most common amongst HPV-positive 
women. They accounted for 24.5% and 13.4%, respectively. As far as both genotypes are 
concerned, the correlation between them and particular age groups was not found (p > 0.05). 
A detailed analysis is presented in Table 4 and 5. 
The individual HPV genotypes have been allocated to three groups:
 Group A — carcinogenic to humans: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 64, 67, 68a,
68b, 73, 82;
 Group B — either probably or possibly carcinogenic to humans: 26, 53, 66, 69;
 Group C — unclassifiable as carcinogenic to humans: 6, 11, 40, 42, 44, 54, 55, 61, 62, 70, 71, 
72, 81, 83, 84, 87, 90, CP6108.
Table 2 presents the basic descriptive statistics and the result of the normality distribution 
of the Shapiro-Wilk test (W). The result is statistically significant for all variables; therefore 
the distribution of the examined variables is highly deviating from normal (p < 0.001). The 
correlation of the occurrence of particular genotypes in specific age groups is statistically 
significant. This correlation is negative, so the frequency of occurrence of particular groups of
HPV genotypes decreases with age (Fig. 1 and Tab. 2). The relationship calculated using 
Spearman's rho coefficient, however, is weak (Tab. 3).
For individual genotypes, the following relationships were found:
 genotype 51(carcinogenic): significantly more frequent in patients under 25 years of age in 
comparison to all other age groups (p = 0.001), significantly more frequent in group 25–30 in 
comparison to group 30–35 (p < 0.001);
 genotype 56 (carcinogenic): significantly more frequent in groups 25–30 and 30–35 in 
comparison to group 40–45 (p = 0.005 and p = 0.024 respectively);
 genotype 59 (carcinogenic): significantly more frequent in patients under 25 years of age in 
comparison to groups 30–35, 35–40 and over 45 years (p < 0.001, p = 0.0015 and p = 0.009, 
respectively) and statistically significantly more frequent in patients in group 25–30 in 
comparison to groups 30–35, 35–40 and over 45 years of age (p = 0.006, p = 0.015 and p = 
0.049, respectively);
 genotype 67 (carcinogenic): significantly more frequent in patients in group 25–30 in 
comparison to groups 30–35 and 35–40 (p < 0.001 and p = 0.004, respectively), significantly 
more frequent in group 25–30 in comparison to groups 30–35 and 35–40 (p = 0.014 and p = 
0.037, respectively) and significantly more frequent in group 30–35 in comparison to group 
over 45 years of age (p = 0.027);
 genotype 73 (carcinogenic): significantly more frequent in patients in group under 25 years of
age in comparison to groups 30–35 and 40–45 (p = 0.016 and p =0.008, respectively) and 
significantly more frequent in group 25–30 in comparison to groups 30–35 and 40–45 (p = 
0.01 and p = 0.01, respectively);
 genotype 66 (possibly carcinogenic): significantly more frequent in patients under 25 years of 
age in comparison to all other age groups (p = 0.0035).
There were also some significant interactions between other genotypes, such as 6, 52, 54 
but because of their non-carcinogenic character, these were not mentioned. 
In case of a positive HPV result, abnormal Pap smear or a clinically suspicious cervix 
image, colposcopy with biopsy was performed. As a result, a biopsy was examined in 321 
patients. In over half of the cases no pathology was found (NILM was diagnosed in 50% of 
patients). LSIL was present in 87 (27%) whereas HSIL in 71 (22%) samples. No squamous 
cervical cancer was histologically confirmed. However, what is noteworthy, two cases of 
adenocarcinomas were detected.
DISCUSSION
This study provides comprehensive information on the HPV prevalence and genotype 
distribution among a cohort of Polish women who were referred to a single center for HPV 
genotyping following either a diagnosis of abnormal cytology or for screening. To our 
knowledge, it is the largest assessment of HPV genotype in Poland to date. Additionally, we 
have not found such a database of one roof patients.
In comparison to another recent study conducted in Poland, we have noticed some 
discrepancies. As expected, the most frequent HPV genotype was 16. It was present in 26% of
all HPV-positive patients compared to 20% in mentioned study. On the other hand, negative 
patients constituted 46.7%, and in the cited study 32.1%. We did not observe the frequent 
occurrence of HPV 18. According to Smolarz et al., it was found in about 14% of women, 
while in our observation, it was in 10th place and occurred twice less often (7.2%) [12]. 
Contrary to the literature, we did not observe genotype 18 occurring frequently. That, 
however, could the result of our focus on a heterogeneous group, where neither SIL nor 
cervical cancer was the criterion. In line with previous studies, HPV 16, 31, and 45 genotypes 
were most often detected in patients diagnosed as ASCUS or LSIL, whereas in patients with 
HSIL, genotypes 16, 33, 18, 31, 56 were the most common [13, 14]. We also provide data for 
the HPV types that are phylogenetically classified as oncogenic, such as HPV types 26, 67, 
69, and 82, but seldomly described in epidemiological studies [15]. Little is known about the 
exact mechanism of HPV-associated carcinogenesis of these rare types due to insufficient 
epidemiological evidences. The biological properties of the rare high-risk HPV types have 
only been investigated in a few studies, which included mostly cervical intraepithelial 
neoplasms lesions and a few cases of invasive cervical cancer [16].
As far as prevention is concerned, it is both important to detect lesions in the early stage 
and to identify risk-factors of carcinogenesis. Early diagnosed HPV-positive patients will be 
eligible for a high risk of cancer development. As a consequence, they will be subjected to 
tighter inspection and follow-up visits. The prevalence of HPV infection among women with 
subclinical or latent disease leads to different results. It depends on the studied population and
used method of HPV detection. The highest percentage of infections is diagnosed using a 
PCR method which is recognized to have the highest sensitivity among all molecular biology 
techniques. It allows to detect the presence of one copy of HPV in 105–106 cells. PCR is now
becoming a common diagnostic technique that is used in numerous laboratories. The results 
obtained from PCR are comparable and allow to avoid their false interpretation. The 
introduction of DNA testing has increased the effectiveness of screening programs in women 
over 30 years of age with the NILM (negative for intraepithelial lesion or malignancy) and 
reduced the number of unnecessary colposcopies and treatment in younger patients [17–20].
What is noticeable, the correlation of the appearance of particular genotypes in specific 
age groups is statistically significant — the frequency of occurrence of particular groups of 
HPV genotypes decreases with age. Over the past four to five decades the assessment of the 
distribution of HPV types in cervical cancer has been crucial for determining the cause of age-
related differences. If the reason is the cohort effect, that could allow us to predict changes in 
the distribution of HPV types in the upcoming years, resulting in improvement of 
implementing preventive HPV-vaccination.
Originally, risk stratification in cervical screening based on the underlying HPV genotype
was suggested in 2003 when the primary clinical HPV assays for screening indicated the 
detection of high-risk HPV genotype was performed either in a research setting or as an in-
house test. Clifford et al., [21] suggested that HPV genotypes 16, 18, and 45 would merit 
closer surveillance than infection with other high-risk HPV genotypes. Subsequently, large-
scale studies of cervical cancers displayed the contribution of different HPV genotypes to 
squamous cell carcinoma and adenocarcinoma. It served as a foundation to determine the 
hierarchy of high-risk HPV genotypes [22]. Throughout the next decade, studies showed that 
genotypes 31, 33, 52, and 58 confer risks similar to HPV 18 and 45, thereby establishing 
impetus for contemplating more complex screening algorithms using genotype-specific risk 
stratification. That resulted in forming more precise colposcopy referral recommendations and
allowed to reduce [23–26] overtreatment. Thus, today's application of HPV diagnostics in 
screening distinguishes between a partial genotyping result for reporting of HPV 16 and 18, 
with the remaining high-risk HPV genotypes as a pooled result. A recent expert review by Xu 
et al., [27] assessing the accuracy of HPV 16/18 genotyping to triage LSIL cytology, points 
out that although the partial genotyping strategy increases the positive predictive value, the 
specificity declines compared with cytology. A more complete differentiation between 
genotypes may improve this strategy.
This work provides estimates of the important contribution of HPV types 16, 31, 51, 56, 
52, 59, and 18. These types should be considered while developing new vaccines with a wider
efficacy range. The early detection of cancers associated with HPV types 16, 31, and 51 
should be considered in screening programs aimed at clinical management based on the HPV 
genotype. Our results indicate which HPV types should be emphasized on when the cross-
protective effects of current vaccines are assessed. What is more, they could come as 
applicable while preparing recommendations for HPV vaccines usage. According to our 
findings those type-specific, high-risk, HPV-DNA-based screening tests and protocols should 
be focused on HPV types 16, 18, 31, 51, 52, 56, and 59. 
CONCLUSIONS
Cervical cancer screening is recommended by clinical practice guidelines for being 
effective cancer preventive method. HPV 16 and 18 partial genotyping is implemented in 
several clinical screening guidelines. Evidence, that have been accumulated for over a decade,
suggests that the definition should be expanded to include risk stratification on the full 
spectrum of high-risk HPV genotypes of women undergoing screening. 
In the future, follow-up and vaccination status of patients may indicate a trend related to 
the extinction of some HPV genotypes in the vaccinated population. The advantage of our 
research is the long duration of the study. Close follow-up should last two years as up to 25% 
of relapses are observed within that period of time. During follow-up, both LSIL and HSIL 
were detected in 158 patients. It is a proof of necessity of supervision over the patients. Two 
cases of adenocarcinoma furtherly confirm that statement. That is why it is essential to build 
trust in the doctor-patient relationship, conduct social campaigns reminding about regular 
checkups and expand diagnostics beyond the exclusive cytology.
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Figure 1. Distribution of HPV positive patients in specific age groups










































































































































































































































M SD LMod. Min. Max. Skew. W p
Group A 0.60 0.84 394 0 5 1.53 0.713 p < 0.001
Group B 0.11 0.35 606 0 2 3.20 0.348 p < 0.001
Group C 0.29 0.63 529 0 4 2.70 0.511 p < 0.001
M — min; SD — standard deviation; W — Shapiro-Wilk test; p — p-value
Table 3. Correlation between age groups and HPV genotypes divided into three groups
rho Spearman p
Age group & Group A –0.23 0.000
Age group & Group B –0.08 0.033
Age group & Group C –0.17 0.000
p — p-value





















43 129 156 120 70 68 586







































48 155 183 132 81 75 674
7.12 23.00 27.15 19.58 12.02 11.13 100
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